Knightpoint Group LLC
A Protected Next-Generation Capsule-Inhalation Platform
Mirai™ opens the capsule rather than piercing it and uses the opened capsule as part of the airflow pathway. The patented architecture has been embodied in a functional development chassis and independently tested at Intertek.
Integrated Capabilities
We integrate the critical device, formulation and aerosol-performance interfaces required to develop combination products.
Proprietary Platform
Device patents granted in the United States and across 38 European countries. The core capsule-opening and aerosol-delivery architecture has been independently tested through a purpose-built development chassis.
- Low resistance for all patients
- Modern, pocket-sized design
Formulation Science
In-house expertise in complex respiratory formulations, including triple-combination ICS/LAMA/LABA products.
- Triple-combination expertise
- In-house triple-combination formulation expertise
- Formulation across every respiratory class
Combination Products
FDA combination product pathway - integrated drug + device products manufactured through our global partnership.
- Global manufacturing partner
- End-to-end control
- Designed to lower patient cost
Why Integrated Control Matters
Most companies are either device specialists or formulation experts - rarely both. Knightpoint Group controls the entire process, enabling optimized product performance and faster development timelines.
Optimized System Performance
Device and formulation designed together, not independently.
Accelerated Development
No waiting on external partners for critical decisions.
Protected IP
Device patents granted in the US and 38 European countries.
The Mirai™ Advantage
Global Design
One patented platform - granted across US + 38 EU markets
Resistance
Cost
Strategic Opportunities
Knightpoint is evaluating confidential strategic opportunities involving acquisition, global development and selected licensing of the Mirai™ platform.